ANDA 70752, held by Abraxis Pharmaceuticals. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 70752 (Nalbuphine), held by Abraxis Pharmaceuticals, was first approved by FDA on Jul 2, 1986, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 1986 | Original application | Approved | None posted |
| Nalbuphine20MG/ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Discontinued |
| Nalbuphine200MG/10ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Discontinued |
| Apr 17, 1991 | Supplement 9Labeling | Approved | None posted |
| Mar 27, 1991 | Supplement 8Labeling | Approved | None posted |
| Feb 20, 1991 | Supplement 7Labeling | Approved | None posted |
| Jan 9, 1990 | Supplement 5Labeling | Approved | None posted |
| Jan 9, 1990 | Supplement 6Labeling | Approved | None posted |
| Jul 2, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters